Expert Ratings for Evolent Health
Evolent Health (NYSE:EVH) has observed the following analyst ratings within the last quarter:
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $52
JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $37 to $52.
RBC Capital Maintains Outperform on Evolent Health, Raises Price Target to $44
RBC Capital analyst Sean Dodge maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $40 to $44.
BTIG Maintains Buy on Evolent Health, Raises Price Target to $50
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $45 to $50.
Piper Sandler Maintains Overweight on Evolent Health, Raises Price Target to $40
Piper Sandler analyst Jessica Tassan maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $35 to $40.
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.